Joseph Jimenez - Novartis CEO, Member of the Executive Committee

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NO</div>
NVS -- USA Stock  

Report: 21st of July 2020  

  CEO
Mr. Joseph S. Jimenez was Chief Executive Officer and Member of the Executive Committee of Novartis Inc. from February 1, 2010 to January 31, 2018. Mr. Jimenez previously held the position of Division Head, Novartis Pharmaceuticals. He joined Novartis in 2007 as Division Head, Novartis Consumer Health. Before that, from 1998 to 2006, he served as president and CEO of the North American and European businesses for the H.J. Heinz Company. He also served on the board of directors of ColgatePalmolive Co. from 2009 to 2015, and of AstraZeneca PLC from 2002 to 2007
Age: 58  CEO Since 2010  MBA    
41 61 324 1111  http://www.novartis.com
Jimenez is a member of the board of directors of General Motors Co. He graduated in 1982 with a bachelor?s degree from Stanford University and in 1984 with a MBA from the University of California, Berkeley, both in the United States.

Joseph Jimenez Latest Insider Activity

Novartis Management Efficiency

Novartis AG has Return on Asset of 5.93 % which means that on every $100 spent on asset it made $5.93 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.16 %, implying that it generated $15.16 on every 100 dollars invested. Novartis management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Novartis Return on Average Equity is relatively stable at the moment as compared to the past year. Novartis reported last year Return on Average Equity of 0.17. As of 07/13/2020, Return on Invested Capital is likely to grow to 0.26, while Return on Average Assets are likely to drop 0.08. Novartis Average Assets are relatively stable at the moment as compared to the past year. Novartis reported last year Average Assets of 131.97 Billion. As of 07/13/2020, Tangible Asset Value is likely to grow to about 71.6 B, while Return on Average Assets are likely to drop 0.08. As of 07/13/2020, Total Liabilities is likely to grow to about 64.8 B. Also, Current Liabilities is likely to grow to about 29.2 B
The company has 36.69 B in debt with debt to equity (D/E) ratio of 0.72, which is OK given its current industry classification. Novartis AG has a current ratio of 0.73, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Found 9 records

CEO Since

Pascal SoriotAstrazeneca PLC
2012
Javier RibesGrifols S A
2015
Justin GoverGW Pharmaceuticals Plc
1999
Andrew WittyGlaxoSmithKline PLC
2008
Deborah WaterhouseGlaxoSmithKline PLC
2020
Brian McNamaraGlaxoSmithKline PLC
2016
Albert RouraGrifols S A
2014
Victor DeuGrifols S A
2017
Emma WalmsleyGlaxoSmithKline PLC
2017

Company Summary

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was founded in 1895 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 109000 people.Novartis AG (NVS) is traded on BATS Exchange in USA. It is located in Lichtstrasse 35 and employs 109,000 people. Novartis AG was previously known as NOVARTIS AG and was traded on BATS Exchange under the symbol NVSEF. Novartis is listed under Pharmaceutical Products category by Fama And French industry classification.

Novartis AG Leadership Team

Ton Buechner, Non-Executive Independent Director
Verena Briner, Non-Executive Independent Member of the Board
Chris Ilsley, President CEO
Steven Baert, Chief People & Organization Officer, Member of the Executive Committee
Richard Saynor, Chief Executive Officer of Sandoz, Member of the Executive Committee
Richard Francis, Member of the Executive Committee and Division Head, Sandoz
Daniel Vasella, Honorary Chairman of the Board
Pierre Landolt, Member of the Board of Directors
Elizabeth Doherty, Non-Executive Independent Director
Erwin Vanhaecke, Head Novartis Group Quality
Elizabeth Barrett, CEO, Novartis Oncology
Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)
Charlotte PamerWieser, Corporate Secretary
Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel
Samir Shah, Global Head Investor Relations
David Epstein, Member of the Executive Committee, Division Head, Pharmaceuticals
Srikant Datar, Non-Executive Independent Director
MarieFrance Tschudin, President of Novartis Pharmaceuticals, Member of the Executive Committee
Simon Moroney, Director
Francesco Balestrieri, Chief Executive Officer of Sandoz, Member of the Executive Committee
Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee
Joerg Reinhardt, Independent Non-Executive Chairman of the Board
Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
Brian McNamara, Member of the Management Board, Division Head, Novartis OTC
Andrews C, Non-Executive Independent Director
Michele Galen, Head Communications
Charles Sawyers, Non-Executive Independent Member of the Board
John Tsai, Head of Global Drug Development and Chief Medical Office, Member of the Executive Committee
Dimitri Azar, Non-Executive Independent Director
Frans Houten, Non-Executive Independent Director
Nancy Andrews, Non-Executive Independent Director
Susanne Schaffert, CEO Novartis Oncology, Member of the Executive Committee
Enrico Vanni, Independent Non-Executive Vice Chairman of the Board
Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee
Robert Weltevreden, Head of Novartis Business Services (NBS), Member of the Executive Committee
Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for Switzerland
Bruno Strigini, CEO of Novartis Oncology, Member of the Executive Committee
Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee
Alex Krauer, Honorary Chairman of the Board
Michael Ball, CEO of Alcon, Member of the Executive Committee
Jeffrey George, Member of the Executive Committee and Division Head, Sandoz
Patrice Bula, Non-Executive Independent Director
Peter Kornicker, Chief Compliance Officer
Andreas Planta, Non-Executive Independent Director
Joseph Jimenez, CEO, Member of the Executive Committee
Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive Director
William Winters, Non-Executive Independent Member of the Board
Ann Fudge, Non-Executive Independent Director
George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility
Paul Arkel, Head of Corporate Strategy and External Affairs
James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee
Felix Ehrat, General Counsel and General Counsel of Novartis International Ag
Harry Kirsch, Chief Financial Officer, Member of the Executive Committee
Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and Diagnostics
Bridgette Heller, Director

Stock Performance Indicators

Did you try this?

Run Idea Breakdown Now

   

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Please also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page